Peter Damsbo, MD, joined Ventac Partners as Partner in June 2009. He has more than 25 years of experience from life science industry and science, including several years in the United States heading up clinical development of diabetes products for Novo Nordisk. Key positions prior to joining Ventac Partners include Chief Medical Officer at Zealand Pharma, Vice President Clinical Drug Development at Novo Nordisk Headquarter, Medical Director Diabetes at Novo Nordisk USA, and Research Fellow at the Steno Diabetes Center.
During his industry career, Peter Damsbo has carried 3 medical projects from preclinical phase through to worldwide registration, and conducted numerous drug concept evaluations as well as been involved in drug licensing deals and due diligence processes.
Peter Damsbo has an extensive experience in interacting with the health authorities in a number of countries, including most notably FDA and EMEA.
Peter Damsbo medical expertise spans over several therapeutic areas, including diabetes, obesity, and metabolic diseases and medical devices. He is associated consultant to US-based KINEXUM and Danish-based KLIFO's Drug Development Counselling groups.
Peter Damsbo received his MD from University of Copenhagen.